Should I try Xolair/Dupixent or are drops enough?

The answer depends on your disease severity and treatment history. For most patients with allergic rhinitis and mild-to-moderate allergic asthma, immunotherapy is the appropriate first step — it is the only treatment proven to modify the underlying allergic disease rather than suppress symptoms. The Cochrane review of sublingual immunotherapy (Radulovic et al. 2010) analyzed 60 RCTs with 4,589 patients and found significant symptom reduction (SMD −0.49, P < 0.00001) and medication reduction (SMD −0.32, P < 0.00001) . Patients who complete 3-5 years of immunotherapy maintain sustained benefit for 7-10+ years after stopping treatment (Penagos et al. 2018). Biologics are designed for a different severity threshold. Xolair was originally approved for moderate-to-severe allergic asthma not controlled by inhaled corticosteroids. Dupixent targets moderate-to-severe atopic dermatitis and asthma driven by type 2 inflammation. These are patients who have already tried and failed multiple therapies.

The following table compares the two treatment approaches across the factors most relevant to patients deciding between them.

Biologics are appropriate when disease severity exceeds what immunotherapy can address alone. Specific scenarios: severe persistent asthma on step 3-4+ therapy (high-dose inhaled corticosteroids plus long-acting beta-agonists) that remains uncontrolled — Xolair reduced asthma exacerbations by approximately 25% in clinical trials for this population. Chronic spontaneous urticaria unresponsive to high-dose antihistamines — Xolair is FDA-approved for this indication at age 12+. Moderate-to-severe atopic dermatitis not controlled by topical therapies — Dupixent is FDA-approved for ages 6 months and older. Chronic rhinosinusitis with nasal polyps — both Xolair and Dupixent have polyp indications. These are conditions where the patient has already failed standard therapy, including potentially immunotherapy, and needs a different mechanism of action.

For the majority of allergy patients — those with allergic rhinitis, mild-to-moderate allergic asthma, or environmental allergies driving their symptoms — immunotherapy is the evidence-based first step and often the only treatment needed. Allergic asthma accounts for approximately 60% of adult asthma cases (AAAAI), and many of these patients can achieve meaningful improvement through allergen-specific immunotherapy without ever needing a biologic. The PAT study demonstrated that 3 years of immunotherapy in children with allergic rhinitis reduced the odds of developing asthma by more than half at 10-year follow-up (Jacobsen et al. 2007). The REACT study confirmed real-world effectiveness over 9 years with reduced asthma medication prescriptions (Fritzsching et al. 2022, N=46,024). Immunotherapy is the only allergy treatment that offers the possibility of stopping medication entirely.

Many allergy patients do not need immunotherapy or biologics. If your symptoms are seasonal, last a few weeks, and are controlled by a single OTC antihistamine — generic cetirizine costs as little as $1/month in bulk, generic fluticasone nasal spray runs $7-10/month — you are managing effectively. Neither a 3-5 year immunotherapy commitment nor a $20,000+/year biologic is warranted for mild, well-controlled allergies. The threshold for considering immunotherapy: you take multiple daily medications and still suffer, your allergies affect sleep or work productivity significantly, or you want to stop relying on daily medication long-term. The threshold for biologics: you have severe disease that has failed immunotherapy, high-dose controller medications, and multiple other therapies.